Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.

has described that ROS1 + NSCLC patients with CD74-ROS1 fusion partners are more likely to present with brain metastases and showed a trend toward improved survival in the non- CD74-ROS1 group when they were treated with crizotinib [ 27 ], suggesting the possibility that fusion partners may have differential responses to therapy.

also in 53,322 other papers